Zhu Xiaoyang, Wang Yan, Liu Zhiyuan, Zhang Xin, Zhang Shuaiqi, Pang Bo, Zhu Shu
Binzhou Medicine University, Yantai, Shandong Province, China.
Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong Province, China.
Medicine (Baltimore). 2025 May 30;104(22):e42678. doi: 10.1097/MD.0000000000042678.
Meningiomas are primarily benign brain tumors that, despite their typically slow growth, often cause significant health issues due to their location. Emerging immunotherapy approaches have sparked optimism regarding treatment outcomes for patients. We conducted a comprehensive Mendelian randomization (MR) analysis, utilizing 731 immune cell phenotypes to explore causal relationships with Brain Meningioma. We employed inverse variance weighted as the primary analysis method, MR-Egger and Maximum likelihood as secondary methods, and Weighted median, Weighted mode, and Simple mode as supplementary methods to ascertain causal links. Additionally, we performed sensitivity tests including heterogeneity tests, pleiotropy tests, reverse MR, leave-one-out analysis, and MR-PRESSO to ensure result robustness. Our study identified potential causal relationships of 7 immune phenotypes with Brain Meningioma, comprising 2 risk factors and 5 protective factors. Specifically, B cell-related phenotypes included CD20 on IgD - CD24 - B cell (P = .048, OR = 1.094, 95% CI = 1.001 - 1.196), CD38 on IgD - CD38 + B cell (P = .004, OR = 0.949, 95% CI = 0.915 - 0.984), and CD38 on IgD - CD38dim B cell (P = .02, OR = 1.073, 95% CI = 1.011 - 1.140). T cell-related phenotypes included Activated CD4 regulatory T cell %CD4 + T cell (P = .013, OR = 0.885, 95% CI = 0.804 - 0.974) and CD25++ CD45RA - CD4 not regulatory T cell %CD4 + T cell (P = .004, OR = 0.905, 95% CI = 0.846 - 0.969). Monocyte-related phenotypes included CD39 on monocyte (P = .022, OR = 0.948, 95% CI = 0.905 - 0.992), and dendritic cell-related phenotype included CD86 + myeloid dendritic cell absolute count (P = .01, OR = 0.914, 95% CI = 0.853 - 0.979).
脑膜瘤主要是良性脑肿瘤，尽管其生长通常缓慢，但由于其位置常常会导致严重的健康问题。新兴的免疫疗法引发了人们对患者治疗结果的乐观情绪。我们进行了一项全面的孟德尔随机化（MR）分析，并利用731种免疫细胞表型来探索与脑脑膜瘤的因果关系。我们采用逆方差加权作为主要分析方法，MR-Egger和最大似然法作为次要方法，以及加权中位数、加权众数和简单众数作为补充方法来确定因果联系。此外，我们进行了敏感性测试，包括异质性测试、多效性测试、反向MR、留一法分析和MR-PRESSO，以确保结果的稳健性。我们的研究确定了7种免疫表型与脑脑膜瘤之间的潜在因果关系，包括2个危险因素和5个保护因素。具体而言，与B细胞相关的表型包括IgD-CD24-B细胞上的CD20（P = 0.048，OR = 1.094，95%CI = 1.001-1.196）、IgD-CD38+B细胞上的CD38（P = 0.004，OR = 0.949，95%CI = 0.915-0.984）以及IgD-CD38dim B细胞上的CD38（P = 0.02，OR = 1.073，95%CI = 1.011-1.140）。与T细胞相关的表型包括活化的CD4调节性T细胞占CD4+T细胞的百分比（P = 0.013，OR = 0.885，95%CI = 0.804-0.974）以及CD25++CD45RA-CD4非调节性T细胞占CD4+T细胞的百分比（P = 0.004，OR = 0.905，95%CI = 0.846-0.969）。与单核细胞相关的表型包括单核细胞上的CD39（P = 0.022，OR = 0.948，95%CI = 0.905-0.992），与树突状细胞相关的表型包括CD86+髓样树突状细胞绝对计数（P = 0.01，OR = 0.914，95%CI = 0.853-0.979）。
